Deals

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent
Multi-specific antibodiesNASDAQ: REGN

Sanofi and Regeneron Expand Alliance with $8B Next‑Generation Antibody Collaboration – Four Long‑Acting Type 2 Inflammation Programs Added Alongside Dupixent

Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a major expansion of their more than 20‑year antibody collaboration, adding four next‑generation, long‑acting antibodies targeting the type 2 inflammation…

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Shionogi to Acquire IntraBio for $2.0B – Rare Neurodegenerative Disease Platform Anchored by FDA‑Approved AQNEURSA Expands Global Portfolio

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Foghorn Therapeutics and Lilly Discontinue FHD‑909 and SMARCA2 Programs – Gene Traffic Control Collaboration Ends After Phase 1 Review

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CRO / CMO / CDMOLionco Pharmaceutical

Lionco Pharmaceutical Partners with Laboratoire Bailly-Creat to Expand Overseas

CAR-TCell-therapy

Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development

Mindray Bio-Medical ElectronicsSHE: 300760

Mindray Bio-Medical Partners with Nanjing Municipal Government to Boost Healthcare Innovation

Shenzhen-Based National Biological Manufacturing Innovation Center Breaks Ground

Show More